2-(3-chlorophenyl)-3-(dimethylamino)acrolein

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-chlorophenyl)-3-(dimethylamino)acrolein
• 英文别名: 2-(3-Chlorophenyl)-3-(dimethylamino)-2-propenal；(2Z)-2-(3-chlorophenyl)-3-(dimethylamino)prop-2-enal；(Z)-2-(3-chlorophenyl)-3-(dimethylamino)prop-2-enal
• 化学式: C₁₁H₁₂ClNO
• 分子量: 209.675
• InChiKey: GCPLFRPOVQSMNZ-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  纳曲酮 、 2-(3-chlorophenyl)-3-(dimethylamino)acrolein 在 乙酸铵 、 溶剂黄146 作用下， 反应 20.0h， 以33%的产率得到5'-(3-chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5α-epoxypyrido[2',3':6,7]morphinan
  参考文献：
  名称：

  Novel ligands for the opioid receptors: synthesis and structure–activity relationships among 5′-aryl and 5′-heteroaryl 17-cyclopropylmethyl-4,5α-epoxypyrido[2′,3′:6,7]morphinans

  摘要：

  A series of pyridomorphinans possessing an aryl (10a-s) or heteroaryl (11a-h) substituent at the 5'-position of the pyridine ring of 17-cyclopropylmethyl-4,5alpha-epoxypyrido[2,3:6,7]morphinan was synthesized and evaluated for binding and functional activity at the opioid delta, mu, and kappa receptors. All of these pyridomorphinans bound with higher affinity at the delta site than at mu or kappa sites. The binding data on isomeric compounds revealed that there exists greater bulk tolerance for substituents placed at the o-position of the phenyl ring than at m- or p-positions. Among the ligands examined, the 2-chlorophenyl (101), 2-nitrophenyl (10n), 2-pyridyl (11a), and 4-quinolinyl (11g) compounds bound to the delta receptor with subnanomolar affinity. Compound 10c with the p-tolyl substituent displayed the highest mu/delta selectivity (ratio = 42) whereas compound 101 with the 2-chlorophenyl substituent displayed the highest kappa/delta selectivity (ratio 23). At 10 muM concentration, the in vitro functional activity determined using [S-35]GTP-gamma-S binding assays showed that all of the compounds were antagonists devoid of any significant agonist activity at the delta, mu, and kappa receptors. Antagonist potency determinations of three selected ligands revealed that the p-tolyl compound 10c is a potent 6 selective antagonist. In the [S-35]GTP-7-S assays this compound had a functional antagonist K-i value of 0.2, 4.52, and 7.62 nM at the delta, mu, and kappa receptors, respectively. In the smooth muscle assays 10c displayed delta antagonist potency with a K-e value of 0.88 nM. As an antagonist, it was 70-fold more potent at the 6 receptors in the MVD than at the mu receptors in the GPI. The in vitro delta antagonist profile of this pyridomorphinan 10c resembles that of the widely used delta selective antagonist ligand naltrindole. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00432-2

文献信息

• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR DE GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2022144274A1

  公开（公告）日：2022-07-07

  The present invention relates to a D-galactopyranose compound of formula (1), wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors, A1 is (a).

  本发明涉及一种公式（1）的D-半乳糖吡喃糖化合物，其中吡喃糖环为beta-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-3抑制剂，其中A1为（a）。
• Substituted 3-alkyl-6-phenyl-1,2,4-triazolo(4,3-a)pyridines, processes for their preparation and pharmaceutical compositions containing them
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0017438A1

  公开（公告）日：1980-10-15

  There are provided novel 3-alkyl-6-(substituted-phenyl)-1,2,4-triazolo[4,3-a]pyridines useful as anxiolytic agents, processes for their preparation and pharmaceutical compositions containing them. The compounds have the formula: wherein R, is hydrogen, alkyl (C1-C4), alkoxy (C,-C4), fluoro, chloro, bromo, trifluoromethyl, cyano, carboxy, alkoxycarbonyl (C2-C5), carboxamido, nitro, amino, acylamino (C1-C4), monoalkylamino (C1-C4) or dialkylamino wherein each alkyl group has up to 4 carbon atoms and R2 is alkyl (C1-C3); or a pharmacologically acceptable acid-addition salt thereof.

  本发明提供了可用作抗焦虑剂的新型 3-烷基-6-（取代苯基）-1,2,4-三唑并[4,3-a]吡啶、其制备工艺以及含有这些化合物的药物组合物。这些化合物的化学式如下 其中 R，是氢、烷基（C1-C4）、烷氧基（C,-C4）、氟、氯、溴、三氟甲基、氰基、羧基、烷氧羰基（C2-C5）、羧酰胺基、硝基、氨基、酰氨基（C1-C4）、单烷基氨基（C1-C4）或二烷基氨基，其中每个烷基最多有 4 个碳原子，R2 是烷基（C1-C3）；或其药理学上可接受的酸加成盐。
• US4209626A
  申请人：——

  公开号：US4209626A

  公开（公告）日：1980-06-24
• US4242515A
  申请人：——

  公开号：US4242515A

  公开（公告）日：1980-12-30
• Novel ligands for the opioid receptors: synthesis and structure–activity relationships among 5′-aryl and 5′-heteroaryl 17-cyclopropylmethyl-4,5α-epoxypyrido[2′,3′:6,7]morphinans
  作者：Subramaniam Ananthan、Naveen K Khare、Surendra K Saini、Peg Davis、Christina M Dersch、Frank Porreca、Richard B Rothman

  DOI：10.1016/s0968-0896(03)00432-2

  日期：2003.9

  A series of pyridomorphinans possessing an aryl (10a-s) or heteroaryl (11a-h) substituent at the 5'-position of the pyridine ring of 17-cyclopropylmethyl-4,5alpha-epoxypyrido[2,3:6,7]morphinan was synthesized and evaluated for binding and functional activity at the opioid delta, mu, and kappa receptors. All of these pyridomorphinans bound with higher affinity at the delta site than at mu or kappa sites. The binding data on isomeric compounds revealed that there exists greater bulk tolerance for substituents placed at the o-position of the phenyl ring than at m- or p-positions. Among the ligands examined, the 2-chlorophenyl (101), 2-nitrophenyl (10n), 2-pyridyl (11a), and 4-quinolinyl (11g) compounds bound to the delta receptor with subnanomolar affinity. Compound 10c with the p-tolyl substituent displayed the highest mu/delta selectivity (ratio = 42) whereas compound 101 with the 2-chlorophenyl substituent displayed the highest kappa/delta selectivity (ratio 23). At 10 muM concentration, the in vitro functional activity determined using [S-35]GTP-gamma-S binding assays showed that all of the compounds were antagonists devoid of any significant agonist activity at the delta, mu, and kappa receptors. Antagonist potency determinations of three selected ligands revealed that the p-tolyl compound 10c is a potent 6 selective antagonist. In the [S-35]GTP-7-S assays this compound had a functional antagonist K-i value of 0.2, 4.52, and 7.62 nM at the delta, mu, and kappa receptors, respectively. In the smooth muscle assays 10c displayed delta antagonist potency with a K-e value of 0.88 nM. As an antagonist, it was 70-fold more potent at the 6 receptors in the MVD than at the mu receptors in the GPI. The in vitro delta antagonist profile of this pyridomorphinan 10c resembles that of the widely used delta selective antagonist ligand naltrindole. (C) 2003 Elsevier Ltd. All rights reserved.